---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-019788"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:41:18.337879+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Glucotrack publishes peer-reviewed study showing CBGM accuracy MARD 6.8% over 240 days in ovine model

## Summary
- Study in Journal of Diabetes Research shows weighted average MARD of 6.8% across 79 IV glucose tolerance tests in ovine model.
- 34 devices implanted in 17 sheep; no device-related adverse events observed over up to 240 days.
- Results support path to IDE submission with FDA for further clinical development toward commercialization.
- Prior first-in-human study demonstrated MARD of 7.7% with 99% data capture and no serious adverse events.

## SEC filing metadata
- accession: 0001493152-26-019788
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315226019788/0001493152-26-019788-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315226019788/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-019788
- JSON: https://secwatch.observer/filing/0001493152-26-019788.json
- Plain text: https://secwatch.observer/filing/0001493152-26-019788.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.